The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Scabies Lesion Lysate (Human) · SCABIES LESION LYSATE (HUMAN) 12 [hp_C]/12[hp_C] · Pellet · Oral · Boiron
NDC 00220-7624-41 · 12 [hp_C] in 1 TUBE · UNAPPROVED MEDICAL GAS · View full market →
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Not scored — fragility is computed for NADAC-priced NDCs.
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Boiron | SCABIES LESION LYSATE (HUMAN) 12 [hp_C]/12[hp_C] | Jul 15, 2026 | Sep 2, 2026 |
| Boiron | SCABIES LESION LYSATE (HUMAN) 15 [hp_C]/15[hp_C] | Jul 15, 2026 | Sep 2, 2026 |
| Boiron | SCABIES LESION LYSATE (HUMAN) 30 [hp_C]/30[hp_C] | Jul 15, 2026 | Sep 2, 2026 |
| Boiron | SCABIES LESION LYSATE (HUMAN) 6 [hp_C]/6[hp_C] | Jul 15, 2026 | Sep 2, 2026 |
| Boiron | SCABIES LESION LYSATE (HUMAN) 7 [hp_X]/1 | Jul 15, 2026 | Sep 2, 2026 |
| Boiron | SCABIES LESION LYSATE (HUMAN) 9 [hp_C]/9[hp_C] | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Psorinum — NDC 00220-7624-41," retrieved September 3, 2026, https://drugdashboards.com/drug/00220762441.
Free to cite with attribution — see how the data is put together.